The level of insider selling is minimal and not concentrated, suggesting no strong negative signal. Traders should monitor for any escalation in selling volume or participation by C-suite executives.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $12.30entry
- T+1 · 9mo ago +0.57%α −0.17% · $12.37
- T+5 · 9mo ago +8.86%α +8.24% · $13.39
- T+20 · 8mo ago −16.10%α −12.15% · $10.32
- T+60 · 6mo ago −28.62%α −36.87% · $8.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
An insider at Arvinas, Inc. (ARVN) sold 4,688 shares in an open-market transaction, generating proceeds of approximately $62,069. This brings the total insider selling over the past 30 days to $101K. The transaction is small relative to the company's $849M market cap and appears consistent with routine, pre-planned trading activity.
Key Financial Metrics
Key Facts
- Insider Houston John G sold 4,688 shares at $13.24 per share for total proceeds of $62,069.12
- This was an open-market sale (Form 4 code 'S')
- Total insider selling over the past 30 days amounts to $101K across 4 transactions
- The total value of recent insider sales is less than 0.01% of Arvinas' $849M market capitalization
Financial Impact
$62,069 in open-market sales by one insider; $101K total over 30 days
Risk Factors
- Continued insider selling, even at low levels, could signal muted confidence in near-term prospects
- Biotech stocks like ARVN are inherently volatile and sensitive to clinical trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (1 trades, 7d window) | cluster-ARVN-1772503070312 |
Track record
21 reports on ARVN
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers